Clinical Trial Update: Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy [Phase 3]

View source ↗

Summary

Phase 3 study evaluating safety and efficacy of PF-06939926 for Duchenne Muscular Dystrophy has posted results; the trial is currently active but not recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• PF-06939926

Snippet

Sponsor: Pfizer | Conditions: Duchenne Muscular Dystrophy | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-06-08